# US 2010/0167320 A1 · Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167320 A1
- Document ID: US20100167320A1
- Status: Published application
- Kind: A1
- Application number: 12/536,830
- Filed: 2009-08-06
- Published: 2010-07-01
- Earliest claimed: 2006-01-30
- Assignees: Life Technologies Corporation
- Inventors: Hans T. Beernink; Mary M. Brodey
- Web page: https://patentgrep.com/patent/US20100167320A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- G01N 2800/2821: Alzheimer
- G01N 2800/2828: Prion diseases
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N 2800/32: Cardiovascular disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to compositions comprising synthetic aggregated peptides (SAPs). The present invention also relates to the use of these SAPs as standards in methods for quantifying substances in a sample. The present invention also relates to methods of detecting, diagnosing and monitoring the progression of an abnormal condition in a subject with the methods comprising determining levels of an aggregated biomarker in a subject by measuring levels of the aggregated biomarker in the subject and correlating these levels to a standard curve, where the standard curve is established using a SAP peptide as the standard.

## Claims

### Claim 1

A method for quantifying a known biomarker in a sample, said method comprising an assay comparing the binding activity of a binding agent to said known biomarker with the binding activity of said binding agent to a synthetic aggregated peptide (SAP).

### Claim 2 (depends on 1)

The method of claim 1 wherein said known biomarker is a peptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein said known peptide is selected from the group consisting of beta amyloid (Aβ), huntingtin, alpha-synuclein, superoxide dismutase-1, (SOD1) and prion peptide.

### Claim 4 (depends on 3)

The method of claim 3, wherein said known peptide is an aggregated oligomer.

### Claim 5 (depends on 4)

The method of claim 4, wherein said aggregated oligomer is an aggregated oligomer of Aβ.

### Claim 6 (depends on 3)

The method of claim 3, wherein said binding agent is an antibody or functional fragment thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein said assay is an assay selected from the group consisting of a colorimetric assay and a radiometric assay.

### Claim 8 (depends on 7)

The method of claim 7, wherein said assay is a colorimetric assay that is an enzyme-linked immunosorbence assay (ELISA).

### Claim 9 (depends on 8)

The method of claim 8, wherein said SAP is a multiple antigenic peptide (MAP).

### Claim 10 (depends on 9)

The method of claim 9, wherein said MAP with more than 4 branches.

### Claim 11 (depends on 9)

The method of claim 9, wherein said MAP is a 4-branched MAP.

### Claim 12 (depends on 11)

The method of claim 11, wherein said MAP comprises at least a portion of a peptide selected from the group consisting of beta amyloid (Aβ), huntingtin, alpha-synuclein, superoxide dismutase-1, (SOD1) and prion peptide.

### Claim 13 (depends on 11)

The method of claim 11, wherein said MAP comprises at least a portion of the Aβ peptide.

### Claim 14 (depends on 13)

The method of claim 13, wherein said portion of Aβ is the N-terminus said Aβ peptide.

### Claim 15 (depends on 14)

The method of claim 14, wherein said N-terminus of said Aβ comprises amino acids 1-10 of SEQ ID NO. 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein said N-terminus of said Aβ comprises amino acids 1-20 of SEQ ID NO:1.

### Claim 17 (depends on 11)

The method of claim 11, wherein said MAP comprises at least a portion of the alpha-synuclein peptide.

### Claim 18 (depends on 17)

The method of claim 17, wherein said portion of alpha-synuclein is near the C-terminus said alpha synuclein peptide.

### Claim 19 (depends on 18)

The method of claim 18, wherein said C-terminus of said alpha-synuclein comprises amino acids 121-125 of SEQ ID NO. 2.

### Claim 20 (depends on 19)

The method of claim 19, wherein said N-terminus of said alpha-synuclein comprises amino acids 116-130 of SEQ ID NO. 2.

### Claim 21

A method of detecting an abnormal condition in a subject, said method comprising
a) detecting the binding activity of a binding agent towards at least one standard to establish a standard curve, said standard comprising a synthetic aggregated peptide (SAP);
b) contacting a sample from said subject with at least one binding agent that is capable of binding a biomarker, wherein said biomarker is an aggregated biomarker;
c) detecting the level binding activity of said binding agent in said sample;
d) correlating said level of binding activity in said sample to said standard curve to determine the levels of said aggregated biomarker in said subject; and
e) comparing the levels of said aggregated biomarker in said subject to normal levels of said aggregated biomarker to determine a difference between measured levels of said aggregated biomarker and normal levels of said aggregated biomarker;
wherein a difference between said measured levels of said aggregated biomarker and said normal levels of said aggregated biomarker, is indicative of an abnormal condition in said subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein said abnormal condition is selected from the group consisting of Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Cruetzfeldt-Jakob Disease, and heart disease or any stage thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein said aggregated biomarker is selected from the group consisting of aggregated beta amyloid (Aβ), aggregated huntingtin, aggregated alpha-synuclein, aggregated superoxide dismutase-1, (SOD1) and aggregated prion peptide.

### Claim 24 (depends on 23)

The method of claim 23, wherein said SAP is a multiple antigenic peptide (MAP).

### Claim 25 (depends on 24)

The method of claim 24 wherein said MAP comprises 4 branches.

### Claim 26 (depends on 25)

The method of claim 25 wherein at least one branch of said MAP standard comprises at least a portion of a peptide selected from the group consisting of beta amyloid (Aβ), huntingtin, alpha-synuclein, superoxide dismutase-1, (SOD1) and prion peptide.

### Claim 27 (depends on 26)

The method of claim 26 wherein said abnormal condition is Alzheimer's Disease, said aggregated biomarker is aggregated Aβ and at least one branch of said MAP standard comprises at least a portion of the beta amyloid (Aβ) peptide.

### Claim 28 (depends on 27)

The method of claim 27 wherein said at least one branch of said MAP standard comprises the N-terminus of said amyloid beta (Aβ) peptide.

### Claim 29 (depends on 28)

The method of claim 28 wherein said N-terminus of Aβ peptide comprises amino acids 1-20 of SEQ ID NO:1.

### Claim 30 (depends on 26)

The method of claim 26 wherein said abnormal condition is Parkinson's Disease, said aggregated biomarker is aggregated alpha-synuclein and at least one branch of said MAP standard comprises at least a portion of an alpha-synuclein peptide.

### Claim 31 (depends on 30)

The method of claim 30 wherein said at least one branch of said MAP standard comprises a portion of the C-terminus of said alpha-synuclein peptide.

### Claim 32 (depends on 31)

The method of claim 31, wherein said C-terminus of said alpha-synuclein peptide comprises amino acids 121-125 of SEQ ID NO:2.

### Claim 33

A composition comprising a branched MAP peptide, wherein at least one branch of said MAP peptide comprises the N-terminus of amyloid beta (Aβ) peptide.

### Claim 34 (depends on 30)

The composition of claim 30, wherein said MAP peptide comprises 4 branches.

### Claim 35 (depends on 31)

The composition of claim 31, wherein each of said 4 branches comprises said N-terminus of Aβ peptide.

### Claim 36 (depends on 32)

The composition of claim 32, wherein said N-terminus of Aβ peptide comprises amino acids 1-20 of SEQ ID NO:1.

### Claim 37 (depends on 33)

The peptide of claim 33, wherein at least one of said 4 branches comprises a peptide other than said N-terminus of Aβ peptide.

### Claim 38

A composition comprising a branched MAP peptide, wherein at least one branch of said MAP peptide comprises a portion of the C-terminus of alpha-synuclein peptide.

### Claim 39 (depends on 38)

The composition of claim 38, wherein said MAP peptide comprises 4 branches.

### Claim 40 (depends on 39)

The composition of claim 39, wherein each of said 4 branches comprises said portion of said C-terminus of alpha-synuclein peptide.

### Claim 41 (depends on 30)

The composition of claim 30, wherein said portion of said C-terminus of alpha-synuclein peptide comprises amino acids 121-125 of SEQ ID NO:1.

### Claim 42 (depends on 41)

The peptide of claim 41, wherein at least one of said 4 branches comprises a peptide other than said portion of said C-terminus of alpha-synuclein peptide.
